10-K: GoodRx Holdings Reports 6% Revenue Increase for 2024, Focuses on Growth and Efficiency

GoodRx Holdings, Inc. reports a 6% increase in revenue for 2024, driven by growth in prescription transactions and pharma manufacturer solutions, while navigating a changing retail pharmacy landscape.

Summary

• GoodRx Holdings, Inc. reported a 6% increase in revenue to $792.3 million for the year ended December 31, 2024, compared to $750.3 million in the previous year.
• The company's adjusted revenue increased by 4% to $792.3 million.
• Net income was $16.4 million, a significant improvement from the net loss of $8.9 million in the prior year.
• Adjusted EBITDA increased to $260.2 million, with an Adjusted EBITDA Margin of 32.8%.
• Prescription transactions revenue increased by 5%, driven by a 7% increase in Monthly Active Consumers.
• Subscription revenue decreased by 8% due to the sunset of the Kroger Savings program.
• Pharma manufacturer solutions revenue increased by 26%, driven by organic growth.
• The company estimates its total addressable market to be between $600 billion and $710 billion.
• GoodRx is focused on delivering consistent and efficient growth by reprioritizing investments and delivering value to consumers.
• The company is managing a changing retail pharmacy landscape, including store closures and heightened renegotiations between pharmacies and PBMs.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with revenue growth and improved profitability. However, it also acknowledges challenges and risks, such as the changing retail pharmacy landscape and competitive pressures, which temper the overall sentiment.

Positives

• Revenue increased by 6% to $792.3 million in 2024.
• Net income was $16.4 million, a significant improvement from the net loss of $8.9 million in the prior year.
• Adjusted EBITDA increased to $260.2 million, representing a 32.8% margin.
• Pharma manufacturer solutions revenue grew by 26% year-over-year.
• The company is focused on delivering consistent and efficient growth by reprioritizing investments and delivering value to consumers.

Negatives

• Subscription revenue decreased by 8% due to the sunset of the Kroger Savings program.
• The company is managing a changing retail pharmacy landscape, including store closures and heightened renegotiations between pharmacies and PBMs.

Risks

• The company's limited operating history and evolving business make it difficult to evaluate future prospects.
• GoodRx may be unsuccessful in achieving broad market education and changing consumer purchasing habits.
• The company may be unable to continue to attract, acquire and retain consumers.
• GoodRx relies significantly on its prescription transactions offering.
• The business is subject to changes in medication pricing and is significantly impacted by pricing structures negotiated by industry participants.
• GoodRx generally does not control the categories and types of prescriptions for which it can offer savings or discounted prices.
• The company relies on a limited number of industry participants.
• GoodRx operates in a very competitive industry.
• The estimated addressable market is subject to inherent challenges and uncertainties.
• The company calculates certain operational metrics using internal systems and tools and does not independently verify such metrics.
• GoodRx may be unable to successfully respond to changes in the market for prescription pricing.
• The company may be unable to maintain a positive perception regarding its platform or maintain and enhance its brand.
• GoodRx is obligated to maintain effective internal control over financial reporting.
• Use of social media, emails and text messages may adversely impact the company's reputation.
• GoodRx depends on its information technology systems, and those of its third-party vendors, contractors and consultants.
• Government regulation of the internet and e-commerce is evolving.
• The business relies on email, mail and other messaging channels.
• GoodRx faces the risk of litigation resulting from unauthorized text messages sent in violation of the Telephone Consumer Protection Act.
• Actual or perceived failures to comply with applicable data protection, privacy and security, advertising and consumer protection laws could adversely affect the business.
• The company may be unable to realize expected benefits from its restructuring and cost reduction efforts.
• GoodRx's ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited.
• The company relies on the performance of members of management and highly skilled personnel.
• A pandemic, epidemic or outbreak of an infectious disease in the United States could adversely impact the business.
• GoodRx may seek to grow its business through acquisitions of, or investments in, new or complementary businesses, technologies or products, or through strategic alliances.
• Restrictions in the company's debt arrangements could adversely affect its operating flexibility.
• The business depends on network and mobile infrastructure and the ability to maintain and scale its technology.
• GoodRx depends on its relationships with third parties.
• Changes in consumer sentiment or laws, rules or regulations regarding the use of cookies and other tracking technologies and other privacy matters could have a material adverse effect on the ability to generate revenues.
• The company is subject to a series of risks related to climate change.
• The increasing focus on environmental, social and governance initiatives could increase costs, harm the company's reputation and adversely impact financial results.
• Risks related to intellectual property could materially adversely impact the business.
• Risks related to the healthcare industry, as well as the impact of healthcare reform legislation and other proposed or future changes, could materially adversely impact the business.
• Risks related to the company's organizational structure, including agreements and relationships with significant stockholders, could materially adversely impact the business.
• GoodRx is, and may become in the future, subject to various legal proceedings and claims that arise in or outside the ordinary course of business.
• The company may be unable to accurately forecast revenue and appropriately plan its expenses in the future.

Future Outlook

GoodRx is focused on delivering consistent and efficient growth by reprioritizing investments to where they are most needed while delivering to consumers what they have come to expect from GoodRx.

Management Comments

• We believe our financial results reflect the significant market demand for our offerings and the value that we provide to the broader healthcare ecosystem.
• We have seen rapid changes in the U.S. retail pharmacy landscape recently with Rite Aid's store closures in addition to announcements of store closures and reduction of footprint from various other retail pharmacies, including Walgreens.
• Future store closures and reduction of footprint from retail pharmacies are expected to have an immediate adverse impact on our prescription volume and prescription transactions revenue.
• As an extension of the changing retail pharmacy landscape, we have seen and continue to expect heightened renegotiations between pharmacies and PBMs as a result of the pharmacies' increased focus on rationalizing their spending, which in turn has had and may have an impact on our prescription transactions revenue.

Industry Context

The report acknowledges the changing retail pharmacy landscape, including store closures and increased negotiations between pharmacies and PBMs, which could impact GoodRx's prescription transactions revenue. The company is also navigating the increasing focus on cost containment in the healthcare industry.

Comparison to Industry Standards

• The report does not provide specific comparisons to industry standards or competitors.
• The report mentions that the U.S. prescriptions market, pharma manufacturer solutions market and telehealth market are highly competitive and subject to ongoing innovation and development.
• The report notes that there is significant concentration in the U.S. healthcare industry, and in particular there are a limited number of PBMs, including pharmacies in-house PBMs, and a limited number of national pharmacy chains.

Management Changes

Legal Proceedings

• The company is involved in various legal proceedings and claims, including consumer privacy class actions, securities class actions, and derivative lawsuits.
• The company has entered into a settlement agreement with the plaintiffs in the SDFL Class Action Matter, which provides for a payment of $13.0 million by the company, subject to final approval of the court.
• The company has entered into a settlement agreement with the NDCA plaintiffs for $25.0 million, subject to approval by the court on June 12, 2025.

Related Party Transactions

• In November 2023, GoodRx repurchased 12.0 million shares of its Class A common stock from related parties, Spectrum Equity VII, L.P., Spectrum VII Investment Managers' Fund, L.P., and Spectrum VII Co-Investment Fund, L.P., for an aggregate consideration of $65.9 million.
• In March 2024, GoodRx repurchased 20.9 million shares of its Class A common stock from related parties, Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. and Spectrum, for an aggregate consideration of $151.4 million.

Stakeholder Impact

• The company's performance impacts shareholders, employees, customers, suppliers, and creditors.
• The company's mission is to help Americans get the healthcare they need at a price they can afford.
• The company's offerings provide significant savings to consumers and can help drive greater medication awareness, access and adherence, faster treatment and better patient outcomes.

Next Steps

• The company plans to continue to invest in and scale its range of product offerings to better address the needs of consumers, provide them with better pricing, and improve their overall healthcare journey.
• GoodRx will continue to pursue strategic opportunities, including commercial relationships and acquisitions, to strengthen its market position and enhance its capabilities.

Key Dates